We came across a bullish thesis on Harrow, Inc. on MVC Investing’s Substack by M. V. Cunha. In this article, we will ...
Harrow is a fast-growing ophthalmic pharma company focused on delivering eye care drugs. Click here to read more about HROW's ...
Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback